{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:33:35Z","timestamp":1790616815998,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.metabol.2022.155246","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T04:05:47Z","timestamp":1656648347000},"page":"155246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)"],"prefix":"10.1016","volume":"134","author":[{"given":"Laura","family":"Valenzuela-Vallejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2022.155246_bb0005","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"Clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"EASL-EASD-EASO","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0010","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2022.155246_bb0015","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2022.155246_bb0020","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/hep.30946","article-title":"The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH","volume":"70","author":"Loomba","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2022.155246_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0030","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2022.155246_bb0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2022.155246_bb0040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00125-019-05024-3","article-title":"Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality","volume":"63","author":"Brouwers","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155246_bb0045","article-title":"Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)","volume":"111S","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155246_bb0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/cld.900","article-title":"Association of Sarcopenia and NAFLD: an overview","volume":"16","author":"Li","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.metabol.2022.155246_bb0055","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/hep.32207","article-title":"High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population","volume":"75","author":"Vilar-Gomez","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2022.155246_bb0060","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease","volume":"23","author":"Perumpail","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2022.155246_bb0065","article-title":"Decoding the pathophysiology of non-alcoholic fatty liver disease progressing to non-alcoholic steatohepatitis: a systematic review","volume":"13","author":"Yaqub","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.metabol.2022.155246_bb0070","article-title":"Immune cell-mediated features of non-alcoholic steatohepatitis","author":"Huby","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.metabol.2022.155246_bb0075","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0080","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11901-018-0425-7","article-title":"Pathogenesis of NASH: the impact of multiple pathways","volume":"17","author":"Noureddin","year":"2018","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.metabol.2022.155246_bb0085","first-page":"499","article-title":"Serum pentraxin 3 concentration in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"129","author":"Trojak","year":"2019","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.metabol.2022.155246_bb0090","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2016.0109","article-title":"Genetic predisposition in nonalcoholic fatty liver disease","volume":"23","author":"Sookoian","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0100","article-title":"The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease","volume":"111S","author":"Perakakis","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155246_bb0105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103584","article-title":"What the new definition of metabolic dysfunction-associated fatty liver disease (MAFLD) left behind: genetically acquired fatty liver disease (GAFLD)","volume":"72","author":"Bril","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.metabol.2022.155246_bb0115","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort","volume":"73","author":"Anstee","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/gut.2009.190801","article-title":"Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease","volume":"59","author":"Dongiovanni","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2022.155246_bb0125","article-title":"Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease","volume":"2","author":"Ghodsian","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.metabol.2022.155246_bb0130","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH - current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0135","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/hep4.1391","article-title":"Body composition and genetic lipodystrophy risk score associate with nonalcoholic fatty liver disease and liver fibrosis","volume":"3","author":"Chen","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.metabol.2022.155246_bb0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrendo.2010.199","article-title":"Lipodystrophy: pathophysiology and advances in treatment","volume":"7","author":"Fiorenza","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2022.155246_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154028","article-title":"Adiponectin and leptin in the diagnosis and therapy of NAFLD","volume":"103","author":"Boutari","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155246_bb0150","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142245","article-title":"Severe insulin resistance syndromes","volume":"131","author":"Angelidi","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2022.155246_bb0155","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2337\/diabetes.53.5.1261","article-title":"Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation","volume":"53","author":"Cohen","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155246_bb0160","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev.med.53.082901.104057","article-title":"Lipotoxic diseases","volume":"53","author":"Unger","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.metabol.2022.155246_bb0165","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hep.20672","article-title":"Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy","volume":"41","author":"Javor","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2022.155246_bb0170","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2022.155246_bb0175","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jnutbio.2007.10.001","article-title":"The role of fatty acids in the development and progression of nonalcoholic fatty liver disease","volume":"19","author":"Gentile","year":"2008","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.metabol.2022.155246_bb0180","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155246_bb0185","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.metabol.2010.10.002","article-title":"Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study","volume":"60","author":"Magkos","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155246_bb0190","article-title":"Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need","volume":"1\u20134","author":"Polyzos","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.metabol.2022.155246_bb0195","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/liv.14828","article-title":"Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population","volume":"41","author":"Ciardullo","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2022.155246_bb0200","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12876-021-01782-w","article-title":"Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.metabol.2022.155246_bb0205","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.metabol.2013.11.004","article-title":"Diet patterns, adipokines, and metabolism: where are we and what is next?","volume":"63","author":"Ko","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155246_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/nu13051442","article-title":"Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development","volume":"13","author":"Vancells Lujan","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.metabol.2022.155246_bb0215","article-title":"Lifestyle and metabolic factors for nonalcoholic fatty liver disease: mendelian randomization study","author":"Yuan","year":"2022","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.metabol.2022.155246_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/nu9040387","article-title":"Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments","volume":"9","author":"Kitade","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.metabol.2022.155246_bb0225","doi-asserted-by":"crossref","first-page":"619","DOI":"10.4254\/wjh.v11.i8.619","article-title":"Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice","volume":"11","author":"Vel\u00e1zquez","year":"2019","journal-title":"World J Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0230","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.3390\/ijms15058713","article-title":"Role of mitochondria in nonalcoholic fatty liver disease","volume":"15","author":"Nassir","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2022.155246_bb0235","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2022.155246_bb0240","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1038\/s41467-018-06931-6","article-title":"Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling","volume":"9","author":"Liang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2022.155246_bb0245","article-title":"Sugar-sweetened beverage, diet soda, and nonalcoholic fatty liver disease over 6 years: the Framingham heart study","author":"Park","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.634344","article-title":"Fructose and non-alcoholic steatohepatitis","volume":"12","author":"Roeb","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.metabol.2022.155246_bb0255","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41574-020-00419-4","article-title":"Role of fructose in NASH defined","volume":"16","author":"Starling","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2022.155246_bb0260","doi-asserted-by":"crossref","DOI":"10.1007\/s00394-022-02831-0","article-title":"Quality of plant-based diets in relation to 10-year cardiovascular disease risk: the ATTICA cohort study","author":"Kouvari","year":"2022","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.metabol.2022.155246_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155136","article-title":"The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials","volume":"129","author":"Angelidi","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155246_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101049","article-title":"Non-alcoholic fatty liver disease and steatohepatitis: state of the art on effective therapeutics based on the gold standard method for diagnosis","volume":"50","author":"Mahjoubin-Tehran","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2022.155246_bb0275","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.metabol.2015.10.019","article-title":"Metabolic health and weight: understanding metabolically unhealthy normal weight or metabolically healthy obese patients","volume":"65","author":"Mathew","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155246_bb0280","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1042\/BST0360935","article-title":"Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese","volume":"36","author":"Tan","year":"2008","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.metabol.2022.155246_bb0285","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrm2391","article-title":"Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes","volume":"9","author":"Guilherme","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.metabol.2022.155246_bb0290","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/cvr\/cvx108","article-title":"The role of infiltrating immune cells in dysfunctional adipose tissue","volume":"113","author":"Guzik","year":"2017","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2022.155246_bb0295","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.metabol.2016.05.013","article-title":"Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155246_bb0300","doi-asserted-by":"crossref","first-page":"92","DOI":"10.23736\/S0391-1977.16.02563-3","article-title":"Adipose tissue, obesity and non-alcoholic fatty liver disease","volume":"42","author":"Polyzos","year":"2017","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.metabol.2022.155246_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10153445","article-title":"Association of body composition and sarcopenia with NASH in obese patients","volume":"10","author":"Schmitz","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2022.155246_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.592373","article-title":"Harnessing muscle-liver crosstalk to treat nonalcoholic steatohepatitis","volume":"11","author":"Chakravarthy","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2022.155246_bb0315","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.clnu.2022.03.022","article-title":"Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: data from the ATTICA cohort study","volume":"41","author":"Kouvari","year":"2022","journal-title":"Clin Nutr"},{"key":"10.1016\/j.metabol.2022.155246_bb0320","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/JOE-15-0533","article-title":"Insulin resistance and sarcopenia: mechanistic links between common co-morbidities","volume":"229","author":"Cleasby","year":"2016","journal-title":"J Endocrinol"},{"key":"10.1016\/j.metabol.2022.155246_bb0325","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fphys.2019.00042","article-title":"Role of myokines in regulating skeletal muscle mass and function","volume":"10","author":"Lee","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.metabol.2022.155246_bb0330","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2213-8587(14)70034-8","article-title":"Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases","volume":"2","author":"Kalyani","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155246_bb0335","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI45887","article-title":"Adipose tissue remodeling and obesity","volume":"121","author":"Sun","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2022.155246_bb0340","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1210\/jc.2011-1665","article-title":"Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin a and follistatin but not myostatin in healthy males","volume":"96","author":"Vamvini","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155246_bb0345","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1210\/jc.2018-01056","article-title":"Physiology of Activins\/Follistatins: associations with metabolic and anthropometric variables and response to exercise","volume":"103","author":"Perakakis","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155246_bb0350","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ecl.2017.01.012","article-title":"Genetics of lipodystrophy","volume":"46","author":"Lightbourne","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.metabol.2022.155246_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21082986","article-title":"Nutrition and genetics in NAFLD: the perfect binomium","volume":"21","author":"Meroni","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2022.155246_bb0360","doi-asserted-by":"crossref","first-page":"7927685","DOI":"10.1155\/2017\/7927685","article-title":"Alcohol consumption in diabetic patients with nonalcoholic fatty liver disease","volume":"2017","author":"Patel","year":"2017","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0365","doi-asserted-by":"crossref","first-page":"8393","DOI":"10.3748\/wjg.v20.i26.8393","article-title":"Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease","volume":"20","author":"Toshikuni","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2022.155246_bb0370","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1530\/EC-18-0499","article-title":"Reduced expression of thyroid hormone receptor \u03b2 in human nonalcoholic steatohepatitis","volume":"7","author":"Krause","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.metabol.2022.155246_bb0375","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.metabol.2022.155246_bb0380","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155246_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it","volume":"6","author":"Begriche","year":"2006","journal-title":"Mitochondrion"},{"key":"10.1016\/j.metabol.2022.155246_bb0390","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis","volume":"52","author":"Rolo","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.metabol.2022.155246_bb0395","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1002\/hep.26285","article-title":"Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect","volume":"57","author":"Rector","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2022.155246_bb0400","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1053\/j.gastro.2005.02.001","article-title":"Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance","volume":"128","author":"Ibdah","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2022.155246_bb0405","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2009.11.030","article-title":"Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model","volume":"52","author":"Rector","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0410","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1113\/jphysiol.2009.169060","article-title":"Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury","volume":"587","author":"Thyfault","year":"2009","journal-title":"J Physiol"},{"key":"10.1016\/j.metabol.2022.155246_bb0415","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/hep.26222","article-title":"Hepatic-specific activation of peroxisome proliferator-activated receptor \u03b3 coactivator-1\u03b2 protects against steatohepatitis","volume":"57","author":"Bellafante","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2022.155246_bb0420","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.pathol.4.110807.092250","article-title":"Mammalian sirtuins: biological insights and disease relevance","volume":"5","author":"Haigis","year":"2010","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.metabol.2022.155246_bb0425","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.mito.2013.09.002","article-title":"Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: a possible role for SirT3 activation","volume":"13","author":"Teodoro","year":"2013","journal-title":"Mitochondrion"},{"key":"10.1016\/j.metabol.2022.155246_bb0430","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2022.155246_bb0435","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/17474124.2018.1530110","article-title":"An update on the recent advances in antifibrotic therapy","volume":"12","author":"Tacke","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2022.155246_bb0440","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/joim.13380","article-title":"Inflammatory and fibrotic mechanisms in NAFLD-implications for new treatment strategies","volume":"291","author":"Lee","year":"2022","journal-title":"J Intern Med"},{"key":"10.1016\/j.metabol.2022.155246_bb9000","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.metabol.2017.12.001","article-title":"FAM3 gene family: A promising therapeutical target for NAFLD and type 2 diabetes","volume":"81","author":"Zhang","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155246_bb9010","doi-asserted-by":"crossref","first-page":"154911","DOI":"10.1016\/j.metabol.2021.154911","article-title":"Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study","volume":"126","author":"Tan","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155246_bb9020","doi-asserted-by":"crossref","first-page":"154708","DOI":"10.1016\/j.metabol.2021.154708","article-title":"Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?","volume":"117","author":"Longo","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155246_bb9030","doi-asserted-by":"crossref","unstructured":"Analysis of Mitochondrial Morphofunctionality in the Pathogenesis Of NAFLD. Tomas Augusto Castillo, Mar\u00eda de la Paz Scribano Parada, Micaela Milagros Rossi, Ismael Fonseca, M\u00f3nica Moya, Mar\u00eda del Carmen Baez, https:\/\/doi.org\/10.1016\/j.metabol.2020.154666.","DOI":"10.1016\/j.metabol.2020.154666"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952200124X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952200124X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:30:26Z","timestamp":1758429026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002604952200124X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":92,"alternative-id":["S002604952200124X"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155246","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155246"}}